All In Biotech

Drug Trial Radar · NCT03321981

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

Last checked: Nov 20, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

105

Actual

Start

Jan 15, 2018

Primary completion

Oct 26, 2022

Study completion Jul 26, 2023

Sponsor

Lead sponsor
Merus B.V.Industry
Sponsor type
Industry
First posted
Oct 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, open-label, multicenter international study will be performed to evaluate the efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2. MCLA-128 (zenocutuzumab) is given in combinations in two metastatic breast cancer (MBC) populations, Human Epidermal Growth Factor Receptor (HER) 2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low HER2 expression (Cohort2). Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially zenocutuzumab is given in combination with trastuzumab in the doublet. After the safety of the doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet. The doublet and triplet combinations are both evaluated in two steps with an initial safety run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for efficacy are included in both the doublet and triplet. In Cohort 2 zenocutuzumab is administered in combination with the same previous endocrine therapy on which progressive disease is radiologically documented. A total of up to 40 patients evaluable for efficacy are included in the Cohort 2.

Conditions

  • Breast Cancer Metastatic

Interventions

  • ZenocutuzumabDrug

    full length immunoglobulin gamma-1 (IgG1) bispecific antibody targeting Human Epidermal Growth Factor Receptor (HER)2 and HER3

  • TrastuzumabDrug

    humanised IgG1 monoclonal antibody

  • VinorelbineDrug

    antineoplastic drug of vinca alkaloid family

  • Endocrine therapyDrug

    same endocrine therapy is administered as the last line of endocrine therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit Rate at 24 WeeksTime frame: 24 weeks

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • HCA Midwest Health

    Kansas City, Kansas

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Institut Jules Bordet

    Brussels, Belgium

  • Grand Hôpital de Charleroi (GHdC)

    Charleroi, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Hôpital Jean Minjoz

    Besançon, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Georges-Francois Leclerc

    Dijon, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmette

    Marseille, France

  • Centre René Huguenin

    Saint-Cloud, France

  • Centre Paul Strauss

    Strasbourg, France

  • Centre Claudius Régaud

    Toulouse, France

  • Institute Gustave Roussy

    Villejuif, France

  • Netherlands Cancer Institute NKI

    Amsterdam, North Holland, Netherlands

  • Champalimaud Clinical Centre

    Lisbon, Portugal

  • Hopistal San Antonio

    Porto, Portugal

  • Instituto Português Oncologia

    Porto, Portugal

  • Vall D'Hebron Institute of Oncology (VHIO)

    Barcelona, Spain

  • Hospital Clinic. C/Villaroel

    Barcelona, Spain

  • Ramon Y Cajal Universitary Hospital

    Madrid, Spain

  • Hospital Universitario 12de Octubre

    Madrid, Spain

  • Instituto Valenciano de Oncologia

    Valencia, Spain

  • Sarah Cannon Research Institute UK

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.